NCT00779636已完成4 期
Efficacy and Safety of Desloratadine 10 mg Daily vs. Placebo in Subjects With Allergic Airway Disease During the Pollen Season
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 506
- 主要终点
- Change in FEV1 averaged over weeks 1 to 4.
研究概览
简要总结
This was a placebo controlled study designed to evaluate the effectiveness of desloratadine in relieving symptoms of allergic airway disease during the pollen season. Patients received desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping study drug).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 - 65 years old
- •at least a two-year history of seasonal allergic rhinitis and the presence of chest symptoms (cough, wheezing, difficulty breathing) associated with the allergy season
- •FEV1 was greater than or equal to 70% of predicted
- •skin test positive (skin prick test)
- •Total Nasal Symptom Severity Score of >= 6 at the Screening Visit.
- •Total Chest Symptom Severity Score of >= 3 at the Screening Visit.
- •Total Frequency of Chest Symptoms and/or Total Frequency of Bronchodilator Use of at least 2 at the Screening Visit
- •Total Nasal Symptom Severity Score was >= 6 on 7 of the 15 run-in diary timepoints.
- •Total Chest Symptom Severity Score was >= 3 on 7 of the 15 run-in diary timepoints
- •Free of any clinically significant disease that would interfere with the study evaluations.
排除标准
- •Subjects who:
- •demonstrated a change in FEV1 of >= 20% between Visit 2 and Visit
- •used >12 puffs of Proventil® HFA (or other beta-2-agonist) on any 2 consecutive days or treatment with nebulized beta-2 agonists during the screening period - between Visit 2 and Visit
- •required chronic use of inhaled or systemic corticosteroids.
- •required regular treatment with nebulized beta2-agonists.
- •required short acting beta-2 agonists use before every exercise session or exposure to an animal.
- •have current or history of frequent (2 or more episodes per year for the past 2 years), clinically significant sinusitis or chronic purulent postnasal drip.
- •have rhinitis medicamentosa or chronic obstructive pulmonary disease (COPD).
- •had an upper or lower respiratory tract or sinus infection that required antibiotic therapy with the last dose 14 days prior to Screening, or who have had a upper or lower viral respiratory infection within 7 days prior to Screening.
- •had nasal structural abnormalities, including large nasal polyps and marked septal deviation that significantly interfered with nasal air flow.
- •in the opinion of the Investigator, were dependent upon nasal, oral or ocular decongestants, nasal topical antihistamines, or nasal steroids.
- •are on immunotherapy (desensitization therapy), unless on a regular maintenance schedule prior to the Screening visit and staying on this schedule for the remainder of the study. Subjects could not receive desensitization treatment within 24 hours prior to a study visit.
- •smoke, or ex-smokers who had smoked within the previous six months.
- •had current evidence of clinically significant hematopoietic, cardiovascular, hepatic, immunologic, renal, neurologic, psychiatric, autoimmune disease, or other disease that precludes the subject's participation in the study or with the subject's ability to complete the diary cards.
- •were morbidly obese (BMI >= 35).
- •were night-shift workers and those who did not have a standard asleep at night / awake during the day cycle.
- •had any history of life threatening asthma attacks or subjects who had been treated in the emergency room or been admitted to the hospital for asthma control within the previous 3 months or more than once in the previous 6 months.
研究组 & 干预措施
Desloratadine 10 mg
Experimental
干预措施: Desloratadine (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in FEV1 averaged over weeks 1 to 4.
时间窗: Over weeks 1 to 4
次要结局
- Interference with sleep and daily activities(ALL TREATMENT VISITS (Day 1, Day 15, and Day 29))
- Change from Baseline in chest symptoms, nasal symptoms, and eye symptom scores(ALL TREATMENT VISITS (Day 1, Day 15, and Day 29))
- Change in FEV1, FVC, FEF(25%-75%), PEFR(ALL TREATMENT VISITS (Day 1, Day 15, and Day 29))
- Number of nocturnal awakenings due to chest symptoms(ALL TREATMENT VISITS (Day 1, Day 15, and Day 29))
- Overall Therapeutic Response to therapy of allergic airway disease symptoms (investigator and joint evaluation)(Day 15 and Day 29)
- Use of Proventil® HFA rescue medication(ALL TREATMENT VISITS (Day 1, Day 15, and Day 29))
研究者
相似试验
已完成
不适用
Response of Desloratadine Syrup in the Relief of Symptoms Associated With Perennial Allergic Rhinitis in Pediatric Patients (Study P04299)RhinitisNCT00704769Organon and Co591
已完成
4 期
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)Chronic Idiopathic UrticariaNCT00536380Organon and Co314
已完成
3 期
Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)Rhinitis, Allergic, SeasonalAsthmaNCT00805324Organon and Co54
已完成
3 期
Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475)Dermatitis, AtopicNCT00817076Organon and Co40
已完成
4 期
Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)Rhinitis, Allergic, SeasonalNCT00805584Organon and Co311